WASHINGTON, D.C.
For the roughly 400,000 Americans living with gout so severe that no pill on the market can touch it, June 27 was supposed to be a day of relief. Instead, it became a lesson in how a drug can do everything right in the body and still get stopped cold by what happens on a factory floor.
Sobi, the Swedish pharmaceutical company behind an experimental gout infusion called NASP, confirmed it received a Complete Response Letter from the FDA on the eve of its decision deadline. The agency's message was blunt but oddly reassuring: no concerns about whether NASP works or whether it's safe. Its problem is with the paperwork, production lines, and contract manufacturers Sobi is relying on to make it.
What Happened Today
The FDA had been reviewing NASP—short for nanoencapsulated sirolimus plus pegadricase—since accepting Sobi's Biologics License Application last September. The PDUFA deadline landed on June 27, 2026. A Complete Response Letter is the FDA's formal "not yet": the application cannot be approved in its current form, but it stops short of an outright rejection.
In NASP's case, the letter zeroed in on chemistry, manufacturing, and controls—the unglamorous but make-or-break category covering consistent production—along with unresolved issues at the contract manufacturing facilities Sobi uses. Crucially, the agency did not flag a single clinical red flag. No efficacy questions. No new safety signal. Just a manufacturing process that isn't locked down enough yet for nationwide rollout.
The Disease Nobody Talks About Until It Ruins Their Life
Gout has a reputation as a punchline—the rich man's disease, brought on by too much red meat and wine. The reality is far grimmer. Gout affects roughly 4% of the U.S. population, making it the most common inflammatory arthritis in American men. It's caused by needle-like uric acid crystals forming in joints, triggering swelling and pain so intense that sufferers describe being unable to tolerate a bedsheet touching an inflamed toe.
Most patients control it with daily oral medications. But an estimated 5% of the roughly 8 million Americans with gout—as many as 400,000 people—don't respond to those pills. Doctors call this uncontrolled, or refractory, gout, and it comes with a brutal price: chalky deposits called tophi under the skin, joint erosion, and higher rates of kidney disease, cardiovascular disease, and diabetes.
For this group, the only approved escalation has been pegloticase (Krystexxa), an infused enzyme that breaks down uric acid. It works—when it works. The problem: a large share of patients develop antibodies against the drug, blunting its effectiveness and raising the risk of infusion reactions. That gap is exactly what NASP was designed to close.
How NASP Is Supposed to Outsmart the Immune System
NASP pairs two components delivered together as a once-every-four-weeks infusion. The first, pegadricase, is a pegylated uricase—in the same family as pegloticase—engineered to dissolve uric acid crystals. The second, nanoencapsulated sirolimus, is the clever part: sirolimus is an immune-modulating drug, and packaging it in nanoparticles alongside the uricase is meant to teach the immune system to tolerate the enzyme instead of attacking it.
If it works as designed, patients should stay on therapy far longer than with pegloticase alone, because their bodies never mount the antibody response that erodes the older drug's effectiveness. It's a more sophisticated, two-pronged approach to a problem that has frustrated rheumatologists for over a decade.
The Data That Got NASP This Far
In the pivotal Phase 3 DISSOLVE I and II studies, NASP met its primary goal of keeping serum uric acid below 6 mg/dL for at least 80% of the sixth month of treatment—the threshold needed to dissolve existing crystal deposits, not just manage symptoms. Pooled across both trials, 51% of patients on the high dose and 43% on the low dose hit that bar.
The benefits extended beyond lab numbers: tophi resolution, fewer gout flares, and meaningful improvements in quality of life. In the 24-week extension of DISSOLVE I, 75% of patients who had responded during the first six months were still responding a full year in—a signal that the tolerogenic design may genuinely be solving the antibody problem. The therapy was described as generally well tolerated.
So Why Did It Still Get Rejected?
Because in the FDA's world, a drug isn't just a molecule—it's a molecule plus a guarantee that every single batch, made at every facility, will be identical to the one used in clinical trials. That guarantee is what the agency says it doesn't have yet. The CRL asked Sobi for more manufacturing data and flagged deficiencies at contract manufacturing organizations—third-party facilities Sobi doesn't fully control, a common and underestimated risk in biologic drug development.
Sobi struck a notably unshaken tone. "We continue to believe strongly in NASP's potential to address the significant unmet need faced by people living with uncontrolled gout," said Lydia Abad-Franch, a Sobi executive. The company said it will meet with the FDA, work with manufacturers to fix the cited deficiencies, and resubmit—a process that could take months to over a year.
A Company Betting Big on Gout
The NASP setback lands at an odd moment for Sobi, which has been aggressively building a gout franchise. Just months before the rejection, the company spent roughly $950 million to acquire Arthrosi Therapeutics, picking up an experimental oral drug called pozdeutinurad, designed to work earlier in the disease. The moves suggest Sobi is trying to build a full pipeline spanning gout's mild and severe ends—a long-term wager that a manufacturing delay is unlikely to derail.
A Complete Response Letter tied purely to manufacturing, with the FDA explicitly clearing efficacy and safety, is a meaningfully different situation than a rejection rooted in the medicine not working or being unsafe. Companies have successfully resubmitted and won approval after CMC-focused CRLs before—it's a slower path, not necessarily a dead one.
What This Means for You
If you or someone you love has uncontrolled gout, NASP is not coming any time soon, and there's no firm new timeline. In the meantime, pegloticase (Krystexxa) remains the only FDA-approved option for refractory cases, and emerging research suggests pairing it with methotrexate can improve response rates by blunting the very antibody response NASP was designed to avoid. It's worth raising that combination with a rheumatologist if pegloticase monotherapy hasn't worked.
Also understand what didn't happen today: the FDA did not say NASP fails to lower uric acid, does not resolve tophi, or poses a safety risk. It said Sobi hasn't yet proven it can reliably manufacture the drug at the standard the agency requires. That's a real and serious bar—manufacturing failures in biologics have caused genuine harm—but it leaves the door open.
The Bottom Line
NASP's story is a reminder that getting a drug approved is really two separate fights: proving it works in the human body, and proving a factory can make it the same way, batch after batch, forever. Sobi appears to have won the first fight decisively. The second one, for now, goes to the FDA. For the hundreds of thousands of Americans whose joints don't respond to anything currently on the shelf, that's a frustrating distinction—but, if Sobi can close the manufacturing gap, not necessarily a permanent one. The company says it's already moving. Patients, for now, keep waiting.
